Cristina Larkin

Cristina Larkin is the Chief Commercial Officer at Spero Therapeutics in Cambridge, MA. Ms. Larkin has over 22 years of experience developing strategic commercial insights for biopharmaceutical companies and their infectious disease products such as Avycaz, Dalvance, Teflaro, Levaquin and Floxin.Prior to joining Spero, she served as Assistant Vice President for Actavis, formerly Forest Laboratories. During that time, Ms. Larkin led the commercial hospital antibiotic franchise team and was responsible for the US launch and execution strategy for several antibiotics. Additionally, she was a member of the business assessments and business development team and played an integral role in the out-licensing of ceftaroline to AstraZeneca, the acquisition of Durata and more.

Ms. Larkin received a bachelor’s degree from Florida State University.

Cristina Larkin is the Chief Commercial Officer at Spero Therapeutics, based in New York, New York, United States, North America. With a background in Biotechnology, Cristina Larkin has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.